Summit Therapeutics Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Summit Therapeutics Inc. (SMMT) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-10-30
- Summit Therapeutics Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-09-30 was $0.00.
- Summit Therapeutics Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-06-30 was $15.01M.
- Summit Therapeutics Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-09-30 was $0.00.
- Summit Therapeutics Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-06-30 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-10-30 | $15.01M derived: sum of 2 quarters · filed 2024-10-30 | $15.01M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $15.01M 10-Q · filed 2024-08-06 | $15.01M 10-Q · filed 2024-08-06 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-10-30 | $0.00 derived: sum of 2 quarters · filed 2024-10-30 | $520.91M 10-Q · filed 2024-10-30 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $520.91M 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |